KALEIDO BIOSCIENCES INC - KLDO STOCK NEWS

Kaleido Biosciences (Nasdaq: KLDO) has appointed Theo Melas-Kyriazi as Chairperson of the Board of Directors, effective August 9, 2021, following Michael Bonney's resignation due to other business commitments. Melas-Kyriazi, a board member since July 2019, brings extensive experience in financial and corporate strategy, having previously served as CFO at Thermo Fisher Scientific. Kaleido continues to advance its microbiome therapies aimed at improving human health, with Melas-Kyriazi expressing commitment to expanding the company's therapeutic pipeline.

Kaleido Biosciences (Nasdaq: KLDO) has announced that CFO William Duke will participate in a fireside chat at the Canaccord Genuity Growth Conference on August 12, 2021, at 2:30 PM ET. The presentation will be accessible via a webcast on the company's Investors & Media webpage. Kaleido focuses on a unique chemistry-driven approach to target the microbiome for disease treatment and health improvement, developing Microbiome Metabolic Therapies (MMTs) to address unmet patient needs. An archived replay will be available for 90 days post-event.

Kaleido Biosciences (Nasdaq: KLDO) will have CEO Dan Menichella present at the JMP Securities Life Sciences Conference on June 17, 2021, at 4 PM ET. This event will focus on Kaleido's innovative approach to microbiome-targeted therapies for disease treatment. Investors can access the live webcast through Kaleido’s website, with an archived replay available for 90 days post-event. The company aims to transform healthcare through its proprietary Microbiome Metabolic Therapies (MMT™), addressing significant unmet patient needs.

Kaleido Biosciences (NASDAQ: KLDO) reported a net loss of $23 million, or $0.58 per share, for Q1 2021, compared to $19.6 million, or $0.64 per share, in Q1 2020. The increased loss was driven by R&D expenses rising to $17.2 million, primarily due to COVID-19 study expenditures. KB109 showed promising results in reducing healthcare utilization and recovery times for mild-to-moderate COVID-19 patients. The company closed a public offering raising approximately $69.4 million and is advancing its IND application for KB109 while expecting topline data for KB295 in ulcerative colitis mid-2021.

Kaleido Biosciences (Nasdaq: KLDO) announced a collaboration with Dr. Robert Jenq from MD Anderson Cancer Center to investigate the use of its Microbiome Metabolic Therapies (MMT™) in preventing febrile neutropenia in patients undergoing hematopoietic stem cell transplantation (HSCT). With 60,000 annual HSCT procedures in the U.S. and Europe, there is an urgent need to address microbiome disruptions caused by treatment regimens. This partnership aims to evaluate MMTs in animal models and potentially improve patient outcomes.

Kaleido Biosciences (Nasdaq: KLDO) announced that CEO Dan Menichella will participate in an analyst-led fireside chat at the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. The event emphasizes Kaleido's innovative, chemistry-driven approach to targeting the microbiome to treat diseases. The webcast will be available at 8 am EDT on Kaleido’s website, with an archived replay accessible for 90 days post-event. Kaleido focuses on developing Microbiome Metabolic Therapies (MMT) aimed at enhancing gut health and addressing unmet medical needs.

Kaleido Biosciences (Nasdaq: KLDO) announced positive results from a study of KB109 for treating mild-to-moderate COVID-19. The study involved 350 patients, revealing a significant reduction in healthcare utilization—62% for those with comorbidities and 51% overall. KB109 also shortened recovery time from 30 to 21 days for patients over 45 or with comorbidities. The company plans to file an Investigational New Drug (IND) application to enter a pivotal registration program. A conference call will discuss these findings.

Kaleido Biosciences (KLDO) reported its fourth quarter and full year 2020 results, showing a net loss of $20 million in Q4 2020 and $81.6 million for the year. The company completed a public offering in February 2021, raising approximately $69.4 million to enhance its cash position of $46.2 million as of year-end. Notable clinical developments include positive interim results from KB109 for COVID-19, with full data expected in Q1 2021, and ongoing trials for KB295 in ulcerative colitis. R&D expenses decreased due to reduced headcount and external costs.

On March 1, 2021, Kaleido Biosciences (Nasdaq: KLDO) announced that its CEO, Dan Menichella, will present a corporate overview at Chardan’s 3rd Annual Microbiome Medicines Summit on March 8, 2021, from 9:30 AM to 9:55 AM EST. This presentation will be virtual, and investors can access a webcast on the company's website. Kaleido focuses on microbiome-targeted therapies to treat diseases and improve health, leveraging its proprietary product platform to develop innovative Microbiome Metabolic Therapies (MMT™) that aim to address significant unmet patient needs.